Regenxbio (RGNX) Tops Q3 EPS by 10c

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.20), $0.10 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $24.63 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Axis Capital Limited Upgrades Zensar Technologies Ltd. (ZENT:IN) to Buy (1)
• Axis Capital Limited Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Reduce (3)